Vancouver, British Columbia, Canada Quark Venture appeared to be the VC, which was created in 2015. The main department of described VC is located in the Vancouver. The company was established in North America in Canada.
The overall number of key employees were 3.
The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year. Speaking about the real fund results, this VC is 21 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2018. This Quark Venture works on 17 percentage points less the average amount of lead investments comparing to the other organizations.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Quark Venture, startups are often financed by Yaletown Partners, Pontifax, Polaris Partners. The meaningful sponsors for the fund in investment in the same round are Pontifax, Yonghua Capital, Yaletown Partners. In the next rounds fund is usually obtained by GF Securities, Polaris Partners, Orient Life.
Among the most popular fund investment industries, there are Biotechnology, Clinical Trials. Among the various public portfolio startups of the fund, we may underline MSI Methylation Sciences, SQZ Biotech, Lyndra Therapeutics Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. The fund has exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.
Related Funds
| Fund Name | Location |
| Alto Partners SGR | Italy, Lombardia, Milano |
| Bankinter | Community of Madrid, Madrid, Spain |
| Bekaert | Belgium, West-Vlaanderen, Zwevegem |
| Brew House | Delhi, India, New Delhi |
| EllisDon | Canada, London, Ontario |
| GameWith | Chiba, Japan, Minato |
| Garden State Life Sciences Venture | Pennsylvania, Philadelphia, United States |
| Golden Section Ventures, LLC | Houston, Texas, United States |
| HackerOne | California, San Francisco, United States |
| Nikko Antfactory | - |
| Octafinance | - |
| OnLine Partners | Denmark, Kolding, Syddanmark |
| Pelecanus Investments | - |
| Sancta Capital Group | Dubai, United Arab Emirates |
| Sequoia Capital Global Equities | California, Menlo Park, United States |
| Sinclair Broadcast Group | Hunt Valley, Maryland, United States |
| Summit Pharmaceuticals International | Chiyoda, Japan |
| Yiguo Group | Changning, China, Shanghai |
| Zheshang Securities | China, Hangzhou, Zhejiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Alpha9 Theranostics | $75M | 14 Dec 2022 | Vancouver, British Columbia, Canada | ||
V-Wave | $98M | 16 Dec 2021 | Israel, North District, Israel | ||
Lyndra Therapeutics | $60M | 24 Jun 2021 | Watertown, Massachusetts, United States | ||
| $32M | 06 Apr 2021 | New York, New York, United States | |||
V-Wave | $28M | 22 Sep 2020 | Israel, North District, Israel | ||
EnClear Therapies | $10M | 19 Feb 2020 | Cambridge, Massachusetts, United States | ||
Volastra Therapeutics | $12M | 11 Feb 2020 | New York, New York, United States | ||
Eyevensys | $30M | 08 Jan 2020 | Ile-de-France | ||
Raziel Health | $22M | 18 Dec 2019 | Florida, United States |
– Lyndra Therapeutics from Watertown, MA develops a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options.
– The company closed a $60.5m Series C financing round.
– The round was led by new investor, AIG Investments, an affiliate of American International Group with participation from new investors Yipinhong Pharmaceutical (USA) Limited, Limitless Ventures and the Catalytic Impact Foundation with ImpactAssets, and existing investors Polaris Partners, Invus, Quark Venture, Mass General Brigham Ventures, HOPU Investments, and Gilead Sciences, Inc.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Alpha9 Theranostics | $75M | 14 Dec 2022 | Vancouver, British Columbia, Canada | ||
V-Wave | $98M | 16 Dec 2021 | Israel, North District, Israel | ||
Lyndra Therapeutics | $60M | 24 Jun 2021 | Watertown, Massachusetts, United States | ||
| $32M | 06 Apr 2021 | New York, New York, United States | |||
V-Wave | $28M | 22 Sep 2020 | Israel, North District, Israel | ||
EnClear Therapies | $10M | 19 Feb 2020 | Cambridge, Massachusetts, United States | ||
Volastra Therapeutics | $12M | 11 Feb 2020 | New York, New York, United States | ||
Eyevensys | $30M | 08 Jan 2020 | Ile-de-France | ||
Raziel Health | $22M | 18 Dec 2019 | Florida, United States |
